CAI — Caris Life Sciences Share News
0.000.00%
Last trade - 00:00- $8.98bn
- $8.58bn
- $812.03m
Caris Life Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services
Caris Life Sciences Inc expected to post earnings of 1 cent a share - Earnings Preview
Caris Life Sciences Q1 revenue rises on demand for molecular profiling services
Brief: Caris Life Sciences Receives Moldx Approval For Caris Chromoseq, Advancing Access To Comprehensive Genomic Profiling For Myeloid Malignancies
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
Brief: Caris Life Sciences Enters New Credit Agreement With Blue Owl Capital And Blackstone - SEC Filing
Brief: Caris Life Sciences Launches Caris Chromoseq For Myeloid Malignancies
Brief: Caris Life Sciences Adds Breast Cancer Signature For Capecitabine To Ai Insights
Brief: Caris Life Sciences Announces Preliminary Fourth Quarter And Full Year 2025 Results
Caris rises on $1.1 billion deal with Genentech
Brief: Caris Life Sciences Announces Collaboration With Genentech
Caris signs Genentech deal worth up to $1.1 billion for rare cancer targets
BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests (updated)
BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut (updated)
Brief: Caris Data Validates TET2 Clonal Hematopoiesis As A Biomarker For Enhanced Immunotherapy Response
U.S. STOCKS ON THE MOVE-SanDisk, MakeMyTrip, Coinbase
Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut (updated)